Allan Lipton
About
In The Last Decade
Allan Lipton
404 papers receiving 20.4k citations
Hit Papers
Peers
Comparison fields: 5 of 164
- Oncology 15.7k
- Radiology, Nuclear Medicine and Imaging 5.8k
- Pulmonary and Respiratory Medicine 5.0k
- Molecular Biology 4.8k
- Orthopedics and Sports Medicine 3.5k
Countries citing papers authored by Allan Lipton
This map shows the geographic impact of Allan Lipton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allan Lipton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allan Lipton more than expected).
Fields of papers citing papers by Allan Lipton
This network shows the impact of papers produced by Allan Lipton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allan Lipton. The network helps show where Allan Lipton may publish in the future.
Co-authorship network of co-authors of Allan Lipton
This figure shows the co-authorship network connecting the top 25 collaborators of Allan Lipton. A scholar is included among the top collaborators of Allan Lipton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allan Lipton. Allan Lipton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 14 | |
| 2 | 11 | |
| 3 | 32 | |
| 4 | 171 | |
| 5 | Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer | 1 |
| 6 | 19 | |
| 7 | Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study breakdown → | 1102 |
| 8 | 3 | |
| 9 | 40 | |
| 10 | 40 | |
| 11 | 31 | |
| 12 | 41 | |
| 13 | Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen | 18 |
| 14 | Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. | 124 |
| 15 | A method for collecting detailed data on direct and indirect medical expenses of cancer patients. | 3 |
| 16 | Pancytopenia induced by aminoglutethimide in the treatment of breast cancer. | 11 |
| 17 | Inhibition of in vitro lymphocyte function by α1 acid glycoprotein, tumor related glycoprotein and fibrinogen degradation products | 7 |
| 18 | Decreased hepatic drug demethylation in patients receiving BCG and chemo immunotherapy | 1 |
| 19 | Immunotherapy employing aerosol BCG | 2 |
| 20 | Successful medical adrenalectomy - The role of altered drug metabolism | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.